Drug Profile
Fadanafil - XuanZhu Pharma
Alternative Names: 5849; XZP 5849Latest Information Update: 04 Jul 2022
Price :
$50
*
At a glance
- Originator XuanZhu Pharma
- Class Erectile dysfunction therapies; Urologics
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Benign prostatic hyperplasia; Erectile dysfunction
Most Recent Events
- 04 Jul 2022 Fadanafil is still in phase-I development in Benign-prostatic-hyperplasia in China (PO, Tablet) (Xuanzhu Biopharm pipeline, July 2022)
- 04 Jul 2022 Fadanafil is still in phase-I development in Erectile-dysfunction in China (PO, Tablet) (Xuanzhu Biopharm pipeline, July 2022)
- 04 Jul 2022 Phase-II clinical trials in Benign prostatic hyperplasia in China (PO) before July 2022 (Xuanzhu Biopharm pipeline, July 2022)